You are here: Industry Insights > plaque psoriasis

News List

FDA Approves of SKYRIZI™ for Moderate to Severe Plaque Psoriasis americanpharmaceuticalreview
April 26, 2019
AbbVie announced the U.S. Food and Drug Administration (FDA) approved SKYRIZI™ (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or photothe
AbbVie, Boehringer Ingelheim's IL-23 inhibitor Skyrizi gains US approval for plaque psoriasis firstwordpharma
April 25, 2019
AbbVie announced that the FDA approved Skyrizi (risankizumab-rzaa) for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
NICE recommends UCB's Cimzia in severe plaque psoriasis pharmafiles
April 23, 2019
NICE has announced its decision to recommend UCB Pharma’s Cimzia (certolizumab pegol) for use on the NHS in England in the treatment of severe plaque psoriasis in patients who have failed to respond to, or are unsuitable for, other systemic treatments.
Mayne Pharma Launches Lexette Foam 0.05% in the US americanpharmaceuticalreview
February 15, 2019
Mayne Pharma has announced the launch of LEXETTE (halobetasol propionate) Foam 0.05% in the United States. LEXETTE, the conditionally-acceptable trade name for halobetasol foam is a new formulation of halobetasol...
Luma begins launch of ultraviolet light-based plaque psoriasis treatment fiercebiotech
December 28, 2018
Luma Therapeutics has launched its light-based treatment for plaque psoriasis symptoms at home, available by prescription through a dermatologist or Luma’s telehealth provider, HealthLens.....
Janssen’s Tremfya shows superiority in plaque psoriasis to Novartis’ drug at 48 weeks pharmaceutical-technology
December 14, 2018
Johnson & Johnson subsidiary Janssen has announced results from its phase III Eclipse trial comparing its Tremfya (guselkumab) with Novartis’ Cosentyx (secukinumab) in adults with moderate to severe plaque psoriasis.....
Sun Pharma bags receipt of European Commission approval expressbpd
September 20, 2018
The drug ILUMETRI (tildrakizumab) is indicated for the treatment of adults with moderate-to-severe chronic plaque psoriasis
FDA approves Sun Pharma’s ILUMYA for treating plaque psoriasis biospectrumasia
March 23, 2018
ILUMYA is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients.
U.S. FDA approves Janssen’s TREMFYA for the treatment of moderate to severe plaque psoriasis biospectrumasia
July 18, 2017
TREMFYA (guselkumab) demonstrated superior results in skin clearance compared with Humira (adalimumab) in head-to-head analyses at weeks 16, 24 and 48.
NICE backs Humira, Enbrel and Stelara for plaque psoriasis in children pharmatimes
July 17, 2017
AbbVie’s Humira, Pfizer’s Enbrel, and Janssen’s Stelara are being recommended as options for treating plaque psoriasis in children and young people on the NHS.

Previous page 1 2 3 4 Next page